Randomized multicenter trial to compare standard lobectomy versus anatomical segmentectomy each plus radical lymphadenectomy in patients with Non-Small Cell Lung Cancer (NSCLC) pT1a pN0 cM0, Stage IA

Randomized multicenter trial to compare standard lobectomy versus anatomical segmentectomy each plus radical lymphadenectomy in patients with Non-Small Cell Lung Cancer (NSCLC) pT1a pN0 cM0, Stage IA - SevLoT1a

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004897

Enrollment

560

Registered

2013-09-02

Start date

2013-10-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: lobectomy and lymphadenectomy Group 2: segmentectomy and lymphadenectomy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - NSCLC smaller 2 cm diameter - no lymphnode metastasis - tumorfree resections margins of min. 2 cm - lungfunction suffient for lobectomy - able to give informed consent

Exclusion criteria

Exclusion criteria: - any lymphnode-involvement, tumorsize over 2 cm diameter - known second malignancy, history of radiation or chemotherapy within the last 5 years - psychatric or other disorders compromising to give writen informed consent or follow-up

Design outcomes

Primary

Measure	Time frame
5 years follow-up: onlogical screening: Overall survival, quality of life	—

Secondary

Measure	Time frame
FU: diseasefree survial, lungfunction, postop. complications, 30 days-mortality	—

Countries

Austria, Germany, Switzerland

Contacts

Public ContactMatthias Altmayer

Ruhrlandklinik - Das Lungenzentrum, Klinik für Thoraxchirurgie und thorakale Endoskopie

matthias.altmayer@ruhrlandklinik.uk-essen.de+49 (0)201/433-4515

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 13, 2026